Palladium Partners LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 2.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 170,544 shares of the company’s stock after selling 3,696 shares during the quarter. Johnson & Johnson comprises 1.7% of Palladium Partners LLC’s holdings, making the stock its 13th largest holding. Palladium Partners LLC’s holdings in Johnson & Johnson were worth $22,173,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Harding Loevner LP bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $124,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $177,000. Finally, Lenox Wealth Management Inc. increased its holdings in shares of Johnson & Johnson by 1.7% during the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after acquiring an additional 24 shares in the last quarter. Institutional investors and hedge funds own 65.53% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) opened at $133.15 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 1 year low of $118.05 and a 1 year high of $148.32. The firm has a market capitalization of $362,940.00, a price-to-earnings ratio of 341.41, a price-to-earnings-growth ratio of 2.17 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the previous year, the firm earned $1.58 earnings per share. The business’s revenue was up 11.5% on a year-over-year basis. equities analysts expect that Johnson & Johnson will post 8.11 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
Several equities research analysts have recently commented on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Citigroup upped their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $146.16.
COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Palladium Partners LLC” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/17/johnson-johnson-jnj-shares-sold-by-palladium-partners-llc.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.